Metabolic Reprogramming By PRDM16 Drives Cytarabine Resistance in Acute Myeloid Leukemia
Junji Ikeda(Yokohama City University), Hideaki Nakajima(National Institute of Advanced Industrial Science and Technology), Kenichi Yoshida(Kyoto University), Norio Shiba(Gunma University), Akio Tawa(Erasmus MC), Seishi Ogawa(Keio University), Hiroyoshi Kunimoto(Yokohama City University), Shin‐ichi Tsujimoto(Yokohama City University), Akihiko Yokoyama(Chiba Cancer Center), Megumi Funakoshi‐Tago(Keio University), Souichi Adachi(Kyoto University), Shuichi Ito(Yokohama City University), Takako Hishiki(Keio University), Noriyo Hayakawa(Keio University), Ikuma Kato(Yokohama City University), Satoru Miyano(Cardiovascular Institute Hospital), Koichi Murakami(Keio University), Tomohiko Tamura(Yokohama City University Medical Center), Yusuke Saito(University of Miyazaki), Takayuki Kurosawa(Yokohama City University), Masanobu Takeuchi(Yokohama City University Hospital), Yasuhide Hayashi(Gunma Children's Medical Center), Tomomi Matsuura(Keio University), Ayaka Miura(Yokohama City University), Daisuke Tomizawa(National Center For Child Health and Development)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Distinct Metabolic Flow Enables Large-Scale Purification of Mouse and Human Pluripotent Stem Cell-Derived Cardiomyocytes
|Cell stem cell|2012|1.1k